IL153764A0 - Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications - Google Patents
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applicationsInfo
- Publication number
- IL153764A0 IL153764A0 IL15376401A IL15376401A IL153764A0 IL 153764 A0 IL153764 A0 IL 153764A0 IL 15376401 A IL15376401 A IL 15376401A IL 15376401 A IL15376401 A IL 15376401A IL 153764 A0 IL153764 A0 IL 153764A0
- Authority
- IL
- Israel
- Prior art keywords
- cell
- antibody
- treatment
- combination
- related applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21770600P | 2000-07-12 | 2000-07-12 | |
US09/772,938 US20020006404A1 (en) | 1999-11-08 | 2001-01-31 | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
PCT/US2001/015677 WO2002004021A1 (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153764A0 true IL153764A0 (en) | 2003-07-06 |
Family
ID=26912176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15376401A IL153764A0 (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305045A1 (en) |
JP (1) | JP2004502742A (en) |
KR (2) | KR20030031957A (en) |
CN (1) | CN1446104A (en) |
AU (2) | AU2001264612C1 (en) |
CA (1) | CA2415100A1 (en) |
IL (1) | IL153764A0 (en) |
MX (1) | MXPA03000306A (en) |
NO (1) | NO20030128L (en) |
SG (1) | SG136804A1 (en) |
WO (1) | WO2002004021A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1176981T3 (en) | 1999-05-07 | 2006-04-10 | Genentech Inc | Treatment of autoimmune diseases with antagonists that bind to B cell surface markers |
JP2004512262A (en) * | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | Non-radioactive anti-CD20 antibody / radiolabeled anti-CD22 antibody combination |
MXPA03002262A (en) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination. |
DE60133479T2 (en) | 2000-10-20 | 2009-04-16 | Chugai Seiyaku K.K. | MODIFIED TPO AGONISTS ANTIBODIES |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002060485A2 (en) * | 2001-01-31 | 2002-08-08 | Idec Pharmaceuticals Corporation | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
WO2003068268A2 (en) * | 2002-02-14 | 2003-08-21 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
JP2004279086A (en) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | Radiation image conversion panel and method for manufacturing it |
EP1609803A4 (en) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | Modified antibody against cd22 and utilization thereof |
SI1613350T1 (en) | 2003-04-09 | 2009-08-31 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
EP1629001A2 (en) | 2003-06-05 | 2006-03-01 | Genentech, Inc. | Blys antagonists and uses thereof |
NZ546173A (en) | 2003-10-16 | 2009-04-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
CA2544368C (en) * | 2003-11-04 | 2014-04-01 | Chiron Corporation | Methods of therapy for b cell-related cancers |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
KR20070029733A (en) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | Method for treating multiple sclerosis |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-cd19 antibodies and uses in oncology |
JP5057967B2 (en) | 2005-03-31 | 2012-10-24 | 中外製薬株式会社 | sc (Fv) 2 structural isomer |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2006114115A1 (en) * | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Combination of antibodies and glucocorticoids for treating cancer |
CN101262885B (en) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | Pharmaceutical compositions containing sc(Fv)2 |
CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
RU2421242C2 (en) | 2005-07-25 | 2011-06-20 | Трабьон Фармасьютикалз, Инк. | Application of single dose of cd20-specific binding molecules |
PT2298815E (en) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | B-cell reduction using cd37-specific and cd20-specific binding molecules |
KR20080039999A (en) | 2005-08-18 | 2008-05-07 | 젠맵 에이/에스 | Therapy with cd4 binding peptides and radiation |
KR20080073725A (en) | 2005-11-01 | 2008-08-11 | 노파르티스 아게 | Uses of anti-cd40 antibodies |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
WO2007124299A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
MX2008015524A (en) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function. |
KR20190140090A (en) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
DK2233149T3 (en) | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
WO2009126944A1 (en) * | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
AR073295A1 (en) | 2008-09-16 | 2010-10-28 | Genentech Inc | METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE. |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
SG10201901417UA (en) | 2009-08-11 | 2019-03-28 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
AR080513A1 (en) | 2010-03-12 | 2012-04-11 | Inmunogen Inc | CD37 UNION MOLECULES AND THEIR IMMUNOCATE PLAYERS |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
DK3050896T3 (en) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Process for the preparation of a polypeptide heteromultimer |
MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
JP6979877B2 (en) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル, エス. アー. | Combination of anti-CD37 immunoconjugate and anti-CD20 antibody |
CR20170562A (en) | 2015-06-24 | 2018-02-01 | Hoffmann La Roche | TRANSFERRINE ANTI-RECEIVER ANTIBODIES WITH DESIGNATED AFFINITY. |
WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
EP3356406A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CA3003399A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
JP7219005B2 (en) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Methods for Streamlining Purification of Fc Region-Containing Polypeptides |
EP3535297B1 (en) | 2016-11-02 | 2022-08-10 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
WO2018217918A2 (en) | 2017-05-24 | 2018-11-29 | Als Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
NZ258392A (en) * | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
2001
- 2001-05-16 SG SG200500152-4A patent/SG136804A1/en unknown
- 2001-05-16 AU AU2001264612A patent/AU2001264612C1/en not_active Ceased
- 2001-05-16 EP EP01939050A patent/EP1305045A1/en not_active Withdrawn
- 2001-05-16 MX MXPA03000306A patent/MXPA03000306A/en not_active Application Discontinuation
- 2001-05-16 KR KR10-2003-7000429A patent/KR20030031957A/en not_active Application Discontinuation
- 2001-05-16 KR KR1020087009742A patent/KR20080039547A/en not_active Application Discontinuation
- 2001-05-16 JP JP2002508475A patent/JP2004502742A/en not_active Abandoned
- 2001-05-16 IL IL15376401A patent/IL153764A0/en unknown
- 2001-05-16 CN CN01814063A patent/CN1446104A/en active Pending
- 2001-05-16 AU AU6461201A patent/AU6461201A/en active Pending
- 2001-05-16 WO PCT/US2001/015677 patent/WO2002004021A1/en active IP Right Grant
- 2001-05-16 CA CA002415100A patent/CA2415100A1/en not_active Abandoned
-
2003
- 2003-01-10 NO NO20030128A patent/NO20030128L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2415100A1 (en) | 2002-01-17 |
JP2004502742A (en) | 2004-01-29 |
CN1446104A (en) | 2003-10-01 |
EP1305045A1 (en) | 2003-05-02 |
AU6461201A (en) | 2002-01-21 |
SG136804A1 (en) | 2007-11-29 |
NO20030128D0 (en) | 2003-01-10 |
KR20030031957A (en) | 2003-04-23 |
KR20080039547A (en) | 2008-05-07 |
WO2002004021A9 (en) | 2003-01-16 |
MXPA03000306A (en) | 2004-04-05 |
WO2002004021A1 (en) | 2002-01-17 |
AU2001264612C1 (en) | 2007-11-22 |
NO20030128L (en) | 2003-03-12 |
AU2001264612B2 (en) | 2007-02-22 |
AU2001264612B8 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153764A0 (en) | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications | |
HK1084109A1 (en) | 2-,3-,4-,or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy 2- | |
AP2002002690A0 (en) | Antibody molecules having specificity for human tumor necrosis factor alphs and use thereof | |
ZA200305825B (en) | Modified antibodies and methods of use | |
GEP20074091B (en) | Cripto blocking antibodies and uses thereof | |
HUP0400284A3 (en) | Recombinant tumor specific antibody and use thereof | |
IL159785A0 (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
IL153970A0 (en) | Promyostatin peptides and methods of using same | |
EP1404366A4 (en) | Combination therapy of gamma-interferon and b cell specific antibodies | |
GB9927332D0 (en) | Novel antibody and uses thereof | |
AU2002364612A8 (en) | Methods and materials for modulating enac-beta | |
EP1418194A4 (en) | Modified polyalkyleneimine and methods of using the same | |
EP1357929A4 (en) | Modulation of immune response and methods based thereon | |
AU2002227272A1 (en) | Ovarian tumor antigen and methods of use therefor | |
AU7832700A (en) | Ovarian tumor antigen and methods of use therefor | |
GB0003474D0 (en) | Closure of bags and the like | |
HK1072538A1 (en) | Immunoregulatory antibodies and uses thereof | |
AU6886301A (en) | Modulation of fas and fasl expression | |
EP1437367A4 (en) | Antibody and use thereof | |
AU141299S (en) | Eating implement | |
GB9823931D0 (en) | Therapeutic antibody composition and use | |
GB9823943D0 (en) | Therapeutic antibody composition and use | |
GB9823936D0 (en) | Therapeutic antibody composition and use | |
GB9823940D0 (en) | Therapeutic antibody composition and use | |
GB9823937D0 (en) | Therapeutic antibody composition and use |